Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable "Off" or End-of-Dose "Wearing Off" Episodes in Patients With Advanced Idiopathic Parkinson's Disease
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2016
Price :
$35
*
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Vectura
- 27 Jul 2016 New trial record